Bupropion
ACCORD-2: AXS-05 delays relapse time to Alzheimer’s disease agitation
SAN DIEGO — AXS-05 was well-tolerated and significantly delayed the time to agitation relapse compared with placebo in patients with Alzheimer’s disease, according to phase 3 data from the ACCORD-2 trial.
Semaglutide, tirzepatide not deemed cost-effective obesity therapies despite benefits
Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and phentermine/topiramate, but their estimated net price is too high for them to be cost-effective, researchers reported.
Smoking cessation prescriptions increase when patients have asthma
BOSTON — Smokers with asthma were more likely to be prescribed a smoking cessation treatment than smokers who did not have asthma, according to a poster at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Tirzepatide, semaglutide more efficacious than other FDA-approved drugs for weight loss
Tirzepatide and semaglutide confer greater weight loss than other FDA-approved obesity medications with no significantly higher risk for adverse events, according to findings from a network meta-analysis published in Obesity.
Less than 1% of Military Health System beneficiaries use an obesity medication
Obesity medications were prescribed to very few Military Health System beneficiaries between October 2017 and September 2022, according to a study published in Obesity.
Most adults with obesity are not prescribed obesity medication
Most adults with obesity were not prescribed an obesity medication from 2015 to 2023, and of those prescribed an agent, 55% had at least one prescription fill, according to study data published in Diabetes, Obesity and Metabolism.
Most adults prescribed obesity drugs discontinue use at 3 months
More than 80% of adults who are prescribed an obesity medication discontinue taking them at 1 year, though persistence rates are higher for adults receiving semaglutide and liraglutide, according to study data.
Certain antidepressants may cause more weight gain over 2 years
DALLAS — Initiation and continued use of certain antidepressants may cause more weight gain over 2 years, according to research presented at ObesityWeek.
Naltrexone/bupropion maintenance therapy for binge-eating disorder superior to placebo
MIAMI BEACH, Fla. — Adults with binge-eating disorder who were given acute naltrexone/bupropion performed better with similar maintenance treatment compared with placebo, per data from the American Society of Clinical Psychopharmacology annual meeting.
Bupropion may promote cocaine abstinence in some opioid users
In addition to a financial incentive, bupropion may help some people being treated for opioid use disorder to stop using cocaine, according to findings published in JAMA Network Open.